Wire · operational-macro
Telix Pharmaceuticals strikes $3.3b merger with German radioisotope giant ITM
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Telix Pharmaceuticals is merging with Germany's ITM Isotope Technologies in a $3.3 billion deal that combines radiopharmaceutical drug development with global isotope supply. The merger secures critical radioisotope access and expands Telix's therapeutic pipeline, targeting completion by the end of FY26.
This Wire brief sits within Fusion42's coverage of Health, and 4 sources have reported it between 21 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
You face a shrinking pool of independent radiopharmaceutical suppliers as major players merge to control both isotope production and drug pipelines. This deal signals urgent pressure to secure supply chains or risk losing market access.
◆ Coverage
4 sources · first reported 21 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics